Hannah Wardill, NHMRC/Hospital Research Foundation Fellow and Lead of Supportive Oncology Research Group at SAHMRI/Uni AdelaideMASCC Board Member, shared a post on LinkedIn:
“Low GRADE does not mean low IMPACT.
Too often, the toxicities that matter most to patients are the ones least visible in clinical trials.
They may be classified as Grade 1 or 2 and considered ‘tolerable’, but they can profoundly affect someone’s ability to work, care for their family, exercise, sleep, and enjoy life.
This was a key message from today’s industry session, ‘Designing Innovative Supportive Care Trials Through Meaningful Patient Collaboration: An Oncodermatology Perspective.’
Hearing from patient advocate Jill Feldmanabout the COCOON trial was a powerful reminder that patients don’t just improve research – they help ensure we measure the outcomes that truly matter.
If we want supportive care trials to be meaningful, patients need to be partners from the very beginning.”
Other articles featuring Hannah Wardill on OncoDaily.